Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% – Time to Sell?

Posted by George Bondi on Oct 10th, 2026

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) were down 6.5% on Thursday. The company traded as low as $10.73 and last traded at $10.7750. 457,490 shares changed hands during trading, a decline of 81% from the average session volume of 2,420,947 shares. The stock had previously closed at $11.52.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

Positive Sentiment: The FDA granted Fast Track designation to VIR-5500, Vir’s PSMA-targeted Pro-XTEN® dual-masked T-cell engager being developed with Astellas Pharma for prostate cancer. Fast Track status may facilitate more frequent FDA interaction and potentially expedite the review process, strengthening the program’s development and commercial prospects. FDA Fast Track designation for VIR-5500
Positive Sentiment: HC Wainwright maintained a Buy rating and a $22 price target, implying substantial potential upside from recent trading levels. The firm raised its FY2030 EPS forecast modestly, to a loss of $0.29 per share from a loss of $0.34, suggesting improved longer-term expectations. HC Wainwright forecast for Vir Biotechnology
Neutral Sentiment: Vir appointed David Liu as executive vice president and chief medical officer, effective October 12, 2026. The leadership addition could support clinical development, but the announcement does not immediately change the company’s financial outlook. David Liu appointed chief medical officer
Neutral Sentiment: Investors are also watching upcoming SOLSTICE Phase 2 hepatitis D data, which could materially influence Vir’s investment narrative when released. No clinical results were reported in the article. SOLSTICE Phase 2 data outlook
Negative Sentiment: HC Wainwright slightly lowered its FY2028 and FY2029 EPS forecasts, to losses of $1.71 and $1.26 per share, respectively, indicating continued expected losses and some pressure on near-term estimates.
Negative Sentiment: Zacks Research downgraded Vir Biotechnology from “Hold” to “Strong Sell,” creating a notable counterweight to HC Wainwright’s bullish view. Zacks rating downgrade

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Zacks Research lowered shares of Vir Biotechnology from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Friday, October 2nd. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research report on Thursday, August 6th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a report on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $21.86.

Check Out Our Latest Stock Analysis on Vir Biotechnology

Vir Biotechnology Price Performance

The firm has a market capitalization of $1.98 billion, a P/E ratio of -6.29 and a beta of 1.59. The business’s 50-day moving average is $10.47 and its 200 day moving average is $9.79.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.14. The business had revenue of $238.95 million during the quarter, compared to analyst estimates of $135.88 million. During the same quarter last year, the firm earned ($0.80) EPS. Vir Biotechnology’s revenue for the quarter was up 19582.5% compared to the same quarter last year. Analysts anticipate that Vir Biotechnology, Inc. will post -1.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Vir Biotechnology

Several institutional investors have recently made changes to their positions in VIR. BlackRock Inc. acquired a new stake in Vir Biotechnology during the second quarter worth about $210,712,000. ARCH Venture Management LLC acquired a new position in shares of Vir Biotechnology in the 2nd quarter valued at approximately $129,353,521. ADAR1 Capital Management LLC acquired a new position in shares of Vir Biotechnology in the 1st quarter valued at approximately $24,593,000. Dimensional Fund Advisors LP lifted its holdings in shares of Vir Biotechnology by 1.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,579,678 shares of the company’s stock worth $23,107,000 after acquiring an additional 43,401 shares during the period. Finally, Pictet Asset Management Holding SA raised its position in Vir Biotechnology by 10,878.9% during the first quarter. Pictet Asset Management Holding SA now owns 1,480,828 shares of the company’s stock valued at $13,268,000 after purchasing an additional 1,467,340 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

About Vir Biotechnology

(Get Free Report)

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing treatments and preventive therapies for serious infectious diseases. The company uses immunologic insights, antibody technology, cellular approaches and other scientific platforms to address diseases in which the immune system plays a central role.

Vir’s research and development programs have included therapies for chronic hepatitis B, influenza, human immunodeficiency virus (HIV) and COVID-19. Its pipeline has included investigational antibody and immunomodulatory candidates such as tobevibart and elebsiran for hepatitis B, as well as programs designed to prevent or treat other viral infections.